April 2, 2025

CHMP recommends pirtobrutinib for relapsed or refractory CLL

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of.

Aggressive B-Cell Lymphomas Lymphoma

Is CAR-T feasible in elderly patients with B-cell lymphoma?

Octogenarians with B-cell lymphoma may be considered for chimeric antigen receptor (CAR) T-cell treatment, according to a study led by.

Read More
Multiple Myeloma

Dr. Lipof discusses Myeloma Action Month

In this video interview, Jodi Lipof, MD, explains why Myeloma Awareness Month matters more than ever.

Read More
Society Updates

1st SOHO Spain debuts in Madrid, bringing together global hematologists

Dr. Garcia-Manero writes about how the first SOHO Spain brought together 400 top international hematologists for its inaugural meeting in.

Read More
Acute Myeloid Leukemia Leukemia News

No benefit to adding pevonedistat to SOC for patients with newly diagnosed AML

The addition of pevonedistat to azacitidine plus venetoclax failed to significantly improve response rates.

Read More
Lymphoma

Potential risk of lymphoma in individuals with large tattoos

Individuals with tattoos, particularly larger ones, may have an increased risk of lymphoma and skin cancer, according to a recent.

Read More
Leukemia Lymphoma Multiple Myeloma News

Do we need to take a closer look at the use of MRD to determine

A Viewpoints article published in The Lancet Haematology, calls for further research into the use of measurable residual disease (MRD).

Read More
Myeloproliferative Neoplasms News Polycythemia Vera

ANVISA approves ropeginterferon alfa-2b in adults with polycythemia vera

The Brazilian Health Regulatory Agency (ANVISA) has approved ropeginterferon alfa-2b (BESREMi) for the treatment of adult patients with polycythemia vera.

Read More
Indolent B-Cell Lymphomas Lymphoma

Liso-cel favorable benefit over mosunetuzumab in 3rd-line R/R follicular lymphoma

Lisocabtagene maraleucel (liso-cel) was found to offer a favorable benefit–risk profile relative to mosunetuzumab as a third-line or later treatment for.

Read More
News Society Updates

SOHO launches new fundraising initiative

SOHO is launching a special fundraising initiative now through its Thirteenth Annual Meeting in Houston, Texas, taking place between September.

Read More
Indolent B-Cell Lymphomas Lymphoma News

EC expands use of liso-cel CAR T-cell therapy for relapsed or refractory follicular lymphoma

The European Commission (EC) has granted approval to lisocabtagene maraleucel (liso-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for.

Read More
Multiple Myeloma

China NMPA approves IND for KPG-818 in relapsed or refractory MM

The Center for Drug Evaluation of the China National Medical Products Administration (NMPA) approved the IND application for KPG-818.

Read More
Acute Lymphoblastic Leukemia News

Nanobody-based CD7 CAR-T induces responses in patients with AML in early-phase study

A phase 1 study found that “naturally selected” CD7 chimeric antigen receptor T-cell (NS7CAR-T) therapy was well-tolerated and induced complete.

Read More

Top Categories

POPULAR NEWS

Meetings

MEMBERS

Editorial Board

Members Strong

Join Us Today and Become a Part of the SOHO Community

Benefits of membership include:

Career

SOHO Career Center

The Career Center provides SOHO members with the ability to find jobs in the field of Hematologic Oncology along with a variety of career advice. Select the 'Career Center' button to explore new job opportunities and career information.

The Career Center Allows SOHO Members to:

To access the SOHO Career Center click the following link.

Verified by MonsterInsights